دورية أكاديمية
أعرض في EDS

Role of Tumor Molecular Profiling With FoundationOne®CDx in Advanced Solid Tumors: A Single-Centre Experience From Romania.

التفاصيل البيبلوغرافية
العنوان: Role of Tumor Molecular Profiling With FoundationOne®CDx in Advanced Solid Tumors: A Single-Centre Experience From Romania.
المؤلفون: Popa AM; Medical Oncology, Elias Emergency University Hospital, Bucharest, ROU., Stejeroiu MA; Medical Oncology, Elias Emergency University Hospital, Bucharest, ROU., Iaciu C; Medical Oncology, Elias Emergency University Hospital, Bucharest, ROU., Olaru M; Medical Oncology, Elias Emergency University Hospital, Bucharest, ROU., Orlov Slavu C; Medical Oncology, Elias Emergency University Hospital, Bucharest, ROU., Parosanu A; Medical Oncology, Elias Emergency University Hospital, Bucharest, ROU., Stanciu IM; Medical Oncology, Elias Emergency University Hospital, Bucharest, ROU., Pirlog C; Medical Oncology, Elias Emergency University Hospital, Bucharest, ROU., Pavel S; Medical Oncology, Elias Emergency University Hospital, Bucharest, ROU., Nitipir C; Medical Oncology, Elias Emergency University Hospital, Bucharest, ROU.
المصدر: Cureus [Cureus] 2023 Dec 18; Vol. 15 (12), pp. e50709. Date of Electronic Publication: 2023 Dec 18 (Print Publication: 2023).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Cureus, Inc Country of Publication: United States NLM ID: 101596737 Publication Model: eCollection Cited Medium: Print ISSN: 2168-8184 (Print) Linking ISSN: 21688184 NLM ISO Abbreviation: Cureus Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Palo Alto, CA : Cureus, Inc.
مستخلص: Background In the field of precision oncology, comprehensive genomic profiling tests play a very important role by providing a complex understanding of the molecular characteristics of malignant tumors. Therefore, next-generation sequencing (NGS) has become a valuable tool in various aspects of cancer care from diagnosis and monitoring to treatment selection and personalized cancer treatment. Our aim was to evaluate the role of tumor molecular profiling in tailored treatment selection. Methods In our study, we conducted a retrospective analysis to assess the practicality of utilizing NGS testing in patients with metastatic solid tumors. The genomic testing was performed on blood or tissue samples from a fresh biopsy, less than six months old, and the expression of programmed death-ligand 1 was evaluated by immunohistochemistry. Results A total of 75 tests were performed on 66 patients between 2019 and 2022, with a success rate of 80%. The most common pathologies were gastro-intestinal tract cancer (26%), breast cancer (14%), non-small cell lung cancer (11%), and pancreatic cancer (11%). There were 9% liquid biopsies and 91% tissue biopsies. From all 66 patients tested, 55 had at least one genetic alteration. The most frequent genetic alteration found was TP53 (n=32) followed by KRAS (n=15) and BRCA1/2 (n=12) mutations. There were nine patients tested (14%) that presented a high tumor mutational burden, and only one patient presented high microsatellite instability. There were 37 patients (56%) with actionable alterations found from which 14 received matched therapy and four patients were enrolled in clinical trials. The NGS testing played a significant role in determining the next therapeutic strategy in 20 out of 66 patients (30.3%). Conclusion From all the patients included in our analysis, 83% had at least one mutation that is known to be of pathogenic significance but only 23% received treatment selected by the analysis of the tumor's genome, and only 6% were included in a clinical trial. This moderate success of personalized medicine using NGS testing highlights the importance of evaluating the factors that could lead to further improvement.
Competing Interests: The authors have declared that no competing interests exist.
(Copyright © 2023, Popa et al.)
References: Cancer Res. 2016 Jul 1;76(13):3690-701. (PMID: 27197177)
Lancet Oncol. 2014 Mar;15(3):267-74. (PMID: 24508104)
Science. 2013 Mar 29;339(6127):1546-58. (PMID: 23539594)
JCO Precis Oncol. 2021 Aug 19;5:. (PMID: 34476329)
Ann Oncol. 2018 Sep 1;29(9):1895-1902. (PMID: 30137196)
Eur J Cancer. 2016 Jul;62:132-7. (PMID: 27189322)
Cancer Discov. 2017 Jun;7(6):586-595. (PMID: 28365644)
N Engl J Med. 2016 Sep 29;375(13):1289-94. (PMID: 27682039)
Oncologist. 2021 Apr;26(4):e588-e596. (PMID: 33325566)
Nature. 2009 Apr 9;458(7239):719-24. (PMID: 19360079)
EClinicalMedicine. 2023 Jun 01;60:102029. (PMID: 37304496)
فهرسة مساهمة: Keywords: cancer genomic profiling; next generation sequencing (ngs); oncology; personalized treatment; targeted therapy
تواريخ الأحداث: Date Created: 20231219 Latest Revision: 20231220
رمز التحديث: 20231220
مُعرف محوري في PubMed: PMC10726298
DOI: 10.7759/cureus.50709
PMID: 38111812
قاعدة البيانات: MEDLINE
الوصف
تدمد:2168-8184
DOI:10.7759/cureus.50709